Asialoglycoprotein Receptor-Targeted Radiopharmaceuticals for Measurement of Liver Function

Title:Asialoglycoprotein Receptor-Targeted Radiopharmaceuticals for Measurement of Liver Function

Volume: 21 Issue: 1

Author(s): W. Yang, X. Zhang and Y. Liu

Affiliation:

Keywords: ASGP receptors, hepatic imaging, liver function, PET, radiopharmaceutical, SPECT.

Abstract: The number of Asialoglycoprotein (ASGP) receptors on the hepatocytes of patients with liver disease is reduced and is thus considered a good indicator for the evaluation of liver function. ASGP receptor-targeted radiopharmaceuticals permit a non-invasive way to evaluate total and regional hepatic function and hepatic functional reserve visually and quantitatively. Over the past three decades, a variety of ASGP receptor-targeted probes have been developed with different molecular backbones (albumin, polymer, small-molecular-weight ligand), different glycol-residues (galactose, lactose, N-acetyl-galactosamine) and different chelating systems suitable for radiolabeling with SPECT isotopes (^99mTc, ¹¹¹In, ⁶⁷Ga, ^131/125I, ¹⁵³Sm) and PET isotopes (⁶⁸Ga, ¹⁸F). In this review, we present an overview of ASGP receptor-targeted radiopharmaceuticals, discuss their chemistry, biodistribution, catabolism and challenge as well as application for measurement of liver function.

Cite this article as:

Yang W., Zhang X. and Liu Y., Asialoglycoprotein Receptor-Targeted Radiopharmaceuticals for Measurement of Liver Function, Current Medicinal Chemistry 2014; 21 (1) . https://dx.doi.org/10.2174/09298673113209990213